AA
CBIO

ALPS Advisors’s Crescent Biopharma CBIO Stock Holding History

ALPS Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-788
Closed -$180K – 801
2020
Q1 		$180K Sell
788
-92
-10% -$35.2K ﹤0.01% 781
2019
Q4 		$466K Buy
880
+18
+2% +$9.74K ﹤0.01% 520
2019
Q3 		$371K Sell
862
-42
-5% -$27K ﹤0.01% 543
2019
Q2 		$1.08M Sell
904
-138
-13% -$165K 0.01% 316
2019
Q1 		$1.3M Buy
1,042
+45
+5% +$51.5K 0.01% 275
2018
Q4 		$944K Buy
997
+235
+31% +$283K 0.01% 314
2018
Q3 		$1.1M Buy
762
+145
+24% +$219K 0.01% 364
2018
Q2 		$995K Buy
617
+156
+34% +$268K 0.01% 340
2018
Q1 		$747K Buy
461
+80
+21% +$166K 0.01% 367
2017
Q4 		$639K Buy
+381
New +$504K ﹤0.01% 359

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's CBIO Position: Q2 2020 in Review

ALPS Advisors sold out of Crescent Biopharma (CBIO) in Q2 2020, closing a stake of 788 shares — an estimated $180K sold.

ALPS Advisors first reported a position in CBIO in Q4 2017 and held it in 10 quarters. The position peaked at $1.3M in Q1 2019. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • ALPS Advisors reported no remaining Crescent Biopharma position as of Q2 2020 after selling out during the quarter.
  • ALPS Advisors sold 788 Crescent Biopharma shares in Q2 2020, an estimated $180K.
  • ALPS Advisors first reported a position in Crescent Biopharma in Q4 2017 and held it in 10 quarters.
  • ALPS Advisors's Crescent Biopharma position peaked at $1.3M in Q1 2019.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on ALPS Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.